#039;&$ 9#,-'$4-'),('7 ! #! #$ % %&&…; 2&03)(,.$4)%,5)(,$:..#,77,7$;-7'6ix — News, calls and decks from 54,000 public companieslt;(0,'$=,,.7$:>#&77$ !(>&5&?*$-(.$/(6,>')& 7$@)7,-7, !……" /> #039;&$ 9#,-'$4-'),('7 ! #! #$ % %&&…; 2&03)(,.$4)%,5)(,$:..#,77,7$;-7'6ix — News, calls and decks from 54,000 public companieslt;(0,'$=,,.7$:>#&77$ !(>&5&?*$-(.$/(6,>')& 7$@)7,-7, !……" /> #039;&$ 9#,-'$4-'),('7 ! #! #$ % %&&…; 2&03)(,.$4)%,5)(,$:..#,77,7$;-7'6ix — News, calls and decks from 54,000 public companieslt;(0,'$=,,.7$:>#&77$ !(>&5&?*$-(.$/(6,>')& 7$@)7,-7, !……" />

Immunitybio, Inc. · NASDAQ:IBRX

Immunitybio — NantKwest — Merger or Acquisition (December 2020)

31 slides from Immunitybio's merger presentation, Dec 21, 2020

  1. Slide 1: ImmunityBio Announces Combination with NantKwest

    Filed by: NantKwest, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NantKwest, Inc. Commission File No.: 001-37507 ImmunityBio Announces Combination with NantKwest to Create a Clinical-Sta

  2. Slide 2: Transaction Overview

    Transaction Overview 2 ImmunityBio, Inc. – Confidential, Not for DistributionTransaction Overview 2 ImmunityBio, Inc. – Confidential, Not for Distribution

  3. Slide 3: Our Opportunity to Lead in Immunotherapy

    Our Opportunity to Lead in Immunotherapy Expansive clinical-stage pipeline and intellectual property. 13 assets in clinical trials, including 11 in Phase II to III clinical trials, as well as a strong global intellectual property portfolio of over 400 issued and pending worldwide patent applications

  4. Slide 4: 2&03)(,.$/00 (&'1,#-%*$45-'6&#07$8,'',#$4&7)')&(,.$'&$ 9#,-'$4-'),('7 ! #! #$$ % %&& !<,$-)*,- /(*$#*.*&(01&*2(- 3)(*…

    2&03)(,.$/00 (&'1,#-%*$45-'6&#07$8,'',#$4&7)')&(,.$'&$ 9#,-'$4-'),('7 ! #! #$$ % %&& !<,$-)*,- /(*$#*.*&(01&*2(- 3)(*4&')%#2'-/(1!2$*&(/-!:)%+)!(&*),-$*&#)*.-4!..()- ;67<-9(..-+.*&5%) -1+*$$!$2- ! #$%&'()*+,-+.*&5%) 1- !! ! #$%&'()*+,-.(*/()- 1+*$$!$2-67-*$/-8-9(..-%550&'(01'(.5-=-*#&%.%2%#1- #$%&'(

  5. Slide 5: 2&03)(,.$4)%,5)(,$:..#,77,7$;-7'$<(0,'$=,,.7$:>#&77$ !(>&5&?*$-(.$/(6,>')& 7$@)7,-7, ! ##$%&'5)) %+&67+('8#(9#.)4! ##…

    2&03)(,.$4)%,5)(,$:..#,77,7$;-7'$<(0,'$=,,.7$:>#&77$ !(>&5&?*$-(.$/(6,>')& 7$@)7,-7, ! ##$%&'5)) %+&67+('8#(9#.)4! ##$%&'!()*+%$,'-#+./'0+&1'! ##$%&'!(//.*(#.&+(%'0+&1' 2.%&30$4&2.%&30$4& H9E*R%2)&#3%&'()*G@<H9*9<; >?*@).$&.$.'+*A$%+2)$.'+*9$%+)2 9KL<6-BM*F8)2$#)1.'+ H9E*R%2)&#3%&'()*G@<H9*A$#',,$24

  6. Slide 6: 41-7,$//$A$///$@-'-$)($ 82BC<(#,7%&(7)D,$=E/82$! # ! #$% #&'()*+ %) *+!$ , -+. / ) $ #

    41-7,$//$A$///$@-'-$)($ 82BC<(#,7%&(7)D,$=E/82$! # ! #$% #&'()*+ 4556$('78()*: ! #$%#&'()$*+,- ,(-./)$%)0(1#'-1*2(3-0($-4556$('78()/0)%($9 ;#$'<.-%'*/)5=($#'()$% ! # $ %&' ( %) *+!$ , -+. / ) $ 0%1 2 $ &%3 4*+5 ) &+0) 6+7 %8 &6%9 # &%) $=41-7,$//$A$///$@-'-$)($ 82BC<(#,7%&(7)D,$=E/82$! # ! #$% #&'()

  7. Slide 7: Significant Market Opportunity for Lead Programs

    Significant Market Opportunity for Lead Programs BCG Unresponsive Non-Muscle Non-Small Cell Lung Cancer Pancreatic Cancer COVID-19 Invasive Bladder Cancer 1L Squamous & Non-Squamous 3L Metastatic COVID-19 Vaccine NSCLC Pancreatic Cancer ~81k ~106k ~31k ~350mm Bladder cancer Targeted 1L patients Targ

  8. Slide 8: H)?15*$IJ%,#),(>,.$E-(-?,0,('$9,-0$K)'1$ 4#&D,($9#->G$L,>&#. 5*;;<(7833</(01> ;%*(58+838##%/(01( =8++%8()8+38$/(01 ! …

    H)?15*$IJ%,#),(>,.$E-(-?,0,('$9,-0$K)'1$ 4#&D,($9#->G$L,>&#. 5*;;<(7833</(01> ;%*(58+838##%/(01( =8++%8()8+38$/(01 ! #$%&'()**+,)-%*+./(017%&-(63&*&'/(0561 2%3() &-4/(056 *61 #$%&'()*+)%,-'.&&$/%*'0 *11 ! #$%&'(#)*+,'-.,/*!1*01 )#828(9 +./(:1)- -$**?(7 ;%? 38-/(!-1@ <2 +(A% ?%/(!-10 B$88+(58&'8$D +4

  9. Slide 9: 9#-(7->')&($@,'-)57$ ! #$%&&'()*#+(,%--.:;<=>&/(+#&-. (),0$#&,.-+#1#+2&/(+#-.344')%,25%- ! #$%&'()'*+,-($ % &.) !6#&'…

    9#-(7->')&($@,'-)57$ ! #$%&&'()*#+(,%--.:;<=>&/(+#&-. (),0$#&,.-+#1#+2&/(+#-.344')%,25%- ! #$%&'()'*+,-($ % &.) !6#&'7,&%)8+-.-+4(-$)#+&/%8-.?@A344')%,25%-&/(+#/-79#+&()9@<A (),0$#&,&/(+#/-79#+& /-(),0 &'+,-($1,2!:;;<&,-*=>.-+>&,-*=4#+?#+ !@'AB#*,,-*'&,-4(+2*-)9%,%-)&C%)*7'9%)? (),0$#&,&/(+#/-79#+(8

  10. Slide 10: Consolidated Pipeline

    Consolidated Pipeline ImmunityBio, Inc. – Confidential, Not for DistributionConsolidated Pipeline ImmunityBio, Inc. – Confidential, Not for Distribution

  11. Slide 11: Unparalleled Pipeline Across Oncology and Infectious Disease

    Unparalleled Pipeline Across Oncology and Infectious Disease Phase Target Indication Pre-clinical Ph I Ph II Ph III ImmunityBio NantKwest BCG Unresponsive NMIBC Carcinoma In-Situ (CIS) Disease Breakthrough & Fast Track II / III ✓ Bladder BCG Unresponsive NMIBC Papillary Disease Fast Track II ✓ 1L Sq

  12. Slide 12: 34567(&#5(&-(&8+'()% <(%-#-55,5,.$/00 (&'1,#-%*$45-'6&#0 <::1%'.4H'3G$%.WX)&. ! #$%&'()*(#&+$ ,)2( #3,#$49844$ , <8#.…

    34567(&#5(&-(&8+'()% <(%-#-55,5,.$/00 (&'1,#-%*$45-'6&#0 <::1%'.4H'3G$%.WX)&. ! #$%&'()*(#&+$ ,)2( #3,#$49844$ , <8#.187)=$77,1 -./$& )01&#,$ /566. &6&'.78#&1/:,43 &7&;$,/ 6&#%2 #%+.RQQ,#-8,)-8CQ(A@(O8CC4 NBE*$%&%3 C08E*$< A@(M(N(O8CC46B#*C*.*B4(08E*$<(&8A@ 0 &$*P- .84N(O8CC4 6+'#%2 (GA,HIJK6C3*F*$B

  13. Slide 13: Selected Summary of Upcoming Catalysts

    Selected Summary of Upcoming Catalysts Ph Trial Status Timing • Full Accrual • Q4 2020 • Initial Readout for FDA • 1H 2021 II / III BCG Unresponsive NMIBC Carcinoma In-Situ (CIS) 2L Bladder • BLA Filing • 2H 2021 • Full Accrual • Q4 2021 II BCG Unresponsive NMIBC Papillary 2L • Initial Readout • Q1

  14. Slide 14: Introduction to ImmunityBio

    Introduction to ImmunityBio ImmunityBio – NantKwest Combinations ImmunityBio, Inc. – Confidential, Not for DistributionIntroduction to ImmunityBio ImmunityBio – NantKwest Combinations ImmunityBio, Inc. – Confidential, Not for Distribution

  15. Slide 15: H,$00)2 !D,#D),K$&6$=&(CE 7>5,$/(D-7)D,$85-..,#$2-(>,# ?1%/ K.8)2 V'/8*2$.)&*37*#23/2)&&'3%*$%0*2)+122)%+)94,#DP3AQ#C…

    H,$00)2 !D,#D),K$&6$=&(CE 7>5,$/(D-7)D,$85-..,#$2-(>,# ?1%/ K.8)2 V'/8*2$.)&*37*#23/2)&&'3%*$%0*2)+122)%+)94,#DP3AQ#C$R&#('#'2&#:3&.* ) #)%&'()*+$%+)2'4#',&$' Q.,,&)'#%'$)/$,/#49#',&$'C&)'#(%#F,$)%.,&'2,$+#2)&)+.'3%*37*=,$00)2*.1:32 SFMHAFT-#5('2#4,#5('24.'#()',$:&%(*$+#'2&,$78 80#11- B-1(&#'()$ /#'

  16. Slide 16: Anktiva+BCG in High-Risk NMIBC – Phase I Results

    Bladder Phase I Results in NMIBC Lung Other Anktiva+BCGinHigh-RiskNMIBC–PhaseIResults Response Assessments Dose FDA granted (intravesicular Patient Stage W12 6M 9M 12M 15M 18M 21M 24M instillation) Fast Track Designation to 1 Pap T1 CR* CR CR CR CR CR CR CR the pivotal trial 100 μg 2 Pap Ta CR* CR C

  17. Slide 17: H,$00)2 41-7,$//$A$///$@-'-$)($ ?1%/ 82BC<(#,7%&(7)D,$=E/82$! # K.8)2 ! #$% #&'()*+ 01$681()I '?&$ #)J),$-./0(0&102.$…

    H,$00)2 41-7,$//$A$///$@-'-$)($ ?1%/ 82BC<(#,7%&(7)D,$=E/82$! # K.8)2 ! #$% #&'()*+ 01$681()I '?&$ #)J),$-./0(0&102.$ 20&3(&4 +&5%-02,4& '81()I '?&$ #)J))6)73(%$ &$8&,$-./0(0&102.$ 20 97%-37+&: *.$% (;&,1&3(&3 +&(%-0<& ZQH#$'#!>#$)/#!?#C4)'2% =%(>&/$=07&?$) *&$8&@AB&,C&D&EFB ZYM[S_?`#Q3\#;!@!`-#a @>

  18. Slide 18: H,$00)2 41-7,$///$@-'-$)($ ?1%/ 82BC<(#,7%&(7)D,$=E/82$$%&'((%)* K.8)2 01$681()I '?&$ #)J)Q$/,8/,)-1,,)R8#,)8#)CK)S& …

    H,$00)2 41-7,$///$@-'-$)($ ?1%/ 82BC<(#,7%&(7)D,$=E/82$$%&'((%)* K.8)2 01$681()I '?&$ #)J)Q$/,8/,)-1,,)R8#,)8#)CK)S& #3/ 97%-37+&: *.$% (;&OEU-$ (>&*%20320&8700&73(0&D&NFB&3 *& /$=07&?$) *&$8&@AB&,C&D&EFB H4*)%0*37*dD*DZDBN*M*+122)%.*0'&)$&)*72))*#$.')%.&*#3.)%.'$,,4* 5$&-00(&(>0&.7%-37+&0 *.$% (<&K

  19. Slide 19: Review of Unmet Need in Lung Cancer

    Bladder Review of Unmet Need in Lung Cancer Lung Other Lung cancer is the second most common cancer in the United States Monoclonal antibodies targeting PD-1 and PD-L1: Nivolumab, pembrolizumab, durvalumab and atezolizumab are FDA- approved 234k 154k Annual New Annual Cases Deaths Current standard o

  20. Slide 20: H,$00)2 41-7,$//3$@-'-$)($+ (?$2-(>,#$ ?1%/ ! # >1$=*?<%$-*49/</ K.8)2 S.7#$B*&3&1#)G8/+,#)8 ')2#8#./08#$, #/)R,4,$U$…

    H,$00)2 41-7,$//3$@-'-$)($+ (?$2-(>,#$ ?1%/ ! # >1$=*?<%$-*49/</ K.8)2 S.7#$B*&3&1#)G8/+,#)8 ')2#8#./08#$, #/)R,4,$U$ ;)*3,4+?&$ #)V)! +#$U8 >?@AB9*CDEFF*.'*- *$ /$. /*=2-'(*AA0G*0-'H(+*+,.-:*$#* )- * ] 4 P $8 C % E %+ $< 82%3 8+ &8 * Q C* + .,#8$E 4# ; C8 3 %48 48 % +Z=^J= A) O= O P #%8+ #4 ]-* P $

  21. Slide 21: H,$00)2 2!;/@CMN$;->>)(,$ ?1%/ 1:.O$FP=$2!;/@CMN$9$2,55$;->>)(, K.8)2 3CC.)('8A(4L%#>)/#0&)&,$'(4)#7+$'94,C#2]/?#(%#f…

    H,$00)2 2!;/@CMN$;->>)(,$ ?1%/ 1:.O$FP=$2!;/@CMN$9$2,55$;->>)(, K.8)2 3CC.)('8A(4L%#>)/#0&)&,$'(4)#7+$'94,C#2]/?#(%#f'::1%3,3/'+$,,4*S1').g* K2$,*($++'%)*377)2&*1%'S1)*$0($%.$/)&*+3:#$2)0* &)$6+()0#(CC.)&#,&%74)%&#&:&)#()#'2&#9$*&#49#$)'(64/(&% ..3*3.8)2*'%h)+.'3%-=$&)0*($++'%)&*'%*0)(),3#:)%.5 I)01

  22. Slide 22: H,$00)2 /00 ()'*8)&Q7$H/;$:(G')D-$4#&?#-0 ?1%/ K.8)2 W59)Q8#8)) 08#$, #/)R,4,$U$ ;)*3,4+?&$ #)V)! +#$U8 *7$ $487)IU$'…

    H,$00)2 /00 ()'*8)&Q7$H/;$:(G')D-$4#&?#-0 ?1%/ K.8)2 W59)Q8#8)) 08#$, #/)R,4,$U$ ;)*3,4+?&$ #)V)! +#$U8 *7$ $487)IU$', 4,)&>)9$1,6$8)*& #1&7)$ )W59)08#$, #/ >:'*1(-Q-9.!$!9*.-/%1(-(19*.*&!%$-1&#/,M-E-%60'%*%A).* 1-& -#%-*($* $65=- * MT?!/($9(-5%)-?!)#1-&)*$19)!+&!%$ )F*&-00%*.('A* 5-#%6 #=0-* MF#22(

  23. Slide 23: !D,#D),K$&6$=-('RK,7'$=R$2,55$4#&. >')&($45-'6&#0 781JN/%78 T,.>%'$#2*78<5)0B.,%*Q,'./ %- <%22*:.,%7#)4'#2*8.22%' G$%…

    !D,#D),K$&6$=-('RK,7'$=R$2,55$4#&. >')&($45-'6&#0 781JN/%78 T,.>%'$#2*78<5)0B.,%*Q,'./ %- <%22*:.,%7#)4'#2*8.22%' G$%.WX)&.*#,$.732:&*73+1&)0* E@A*'%*$*H3 * 3%*&+$,)*#2301+.'3%*$%0* BD>EFBD!GHI+JJI+JK #)2732:&*+32)* :$%17$+.12'%/*37*GW*+),,* 71%+.'3%&* ..4#)&*.3*&1##32.* %)+)&&$24*732* #####77777888

  24. Slide 24: A$%+2)$.'+ 4-(>#,-')>$2-(>,#$4#&?#-0$!D,#D),K H2)$&. 4@S+M$'C1-=R @)2J), XU,1U$,Y)8 ')!??1&843KZ)S,#8/#8#$4)08 41,8#$…

    A$%+2)$.'+ 4-(>#,-')>$2-(>,#$4#&?#-0$!D,#D),K H2)$&. 4@S+M$'C1-=R @)2J), XU,1U$,Y)8 ')!??1&843KZ)S,#8/#8#$4)08 41,8#$4)*8 4,1)Q8#8 >! H+.8-*- )*-:)$N$,&0.%. *%$;0. ()*O.+2*$##P+2(P'2(:#*45*%(::'* - )*$+2(,*-/( +'*1'%V(/-*-/#)*3.(-9% +.(&(-)( !11!%$-!$- +*&!($&1-V!&'-*/?*$9(/-/!1(*1( %&'# ()# O%%1$,*

  25. Slide 25: A$%+2)$.'+ 9#)%5,$=,?-')D,$8#,-7'$2-(>,#$T9=82U$4#&?#-0 H2)$&. !D,#D),K$4@C+M$'C1-=R @)2J), XU,1U$,Y)8 ')!??1&843:<G*…

    A$%+2)$.'+ 9#)%5,$=,?-')D,$8#,-7'$2-(>,#$T9=82U$4#&?#-0 H2)$&. !D,#D),K$4@C+M$'C1-=R @)2J), XU,1U$,Y)8 ')!??1&843:<G*)Q8#8 >Q().- *?1&;1,//$& )>1,,)/.1U$U87)Y8/) !'+ CL[E)6& #3/O.+2*;().- *$8(,-::*'&,8.8-:* GH^WK() B ; _8&#4(] %#- ( *&# $#*KP[K)6& #3/)#&)'8#, 1 %48 48(O * + #$* C (&# O%%1$,* O%%1$,*

  26. Slide 26: A$%+2)$.'+ E,#G,5$2,55$2-#>)(&0-$4#&?#-0$!D,#D),K H2)$&. +$@&%A1*B*/C8DE*3145 @)2J), XU,1U$,Y!??1&843)8 ')Q,U,7&?6, #…

    A$%+2)$.'+ E,#G,5$2,55$2-#>)(&0-$4#&?#-0$!D,#D),K H2)$&. +$@&%A1*B*/C8DE*3145 @)2J), XU,1U$,Y!??1&843)8 ')Q,U,7&?6, #)078 !@%)?7#>(+4L&,'92L-.L5(;+,7'$,($*-.=,('+,-($%,/L MN>:OL#I8+#&&%)?CL-..>,/#>&/#7.L 0L()9L(1#7'4(ALD(),%L ,%-!#% + PN>Q:L*/#*=8-%),L%)/%A%,-+G O%%1$,*A$.')%.&* G)X*&12('('%/* !R%+&

  27. Slide 27: B /0)%($= ) $ # &%) $B /0)%($= ) $ # &%) $

    B /0)%($= ! # $ %&' ( %) *+!$ , -+. / ) $ 0%1 2 $ &%3 4*+5 ) &+0) 6+7 %8 &6%9 # &%) $B /0)%($= ! # $ %&' ( %) *+!$ , -+. / ) $ 0%1 2 $ &%3 4*+5 ) &+0) 6+7 %8 &6%9 # &%) $

  28. Slide 28: 2&0%,55)(?$F'#-',?)>$L-')&(-5,$6&#$2&03)(-')&($ .../01/01/2/233 !<,$-)*,- /(*$#*.*&(01&*2(- 3)(*4&')%#2'-/(1!2$*&(/-!…

    2&0%,55)(?$F'#-',?)>$L-')&(-5,$6&#$2&03)(-')&($ .../01/01/2/233 !<,$-)*,- /(*$#*.*&(01&*2(- 3)(*4&')%#2'-/(1!2$*&(/-!:)%+)!(&*),-$*&#)*.-4!..()- ;67<-9(..-+.*&5%) -1+*$$!$2- ! #$%&'()*+,-+.*&5%) 1- 1+*$$!$2-67-*$/-8-9(..-%550&'(01'(.5-=-*#&%.%2%#1- !! ! #$%&'()*+,-.(*/()- 1&( -9(..-67-+.*&5%) +.*&5%

  29. Slide 29: Next Steps

    Next Steps • SEC clearance of registration statement / proxy Required • NantKwest shareholder vote (Q1 2021) Approvals • Transaction subject to customary closing conditions – until closing, NantKwest will continue to operate as a separate and independent company • Registration statement / proxy • Ja

  30. Slide 30: Forward-Looking Statements

    Forward-Looking Statements • This presentation contains forward-looking statements relating to the proposed transaction involving NantKwest, Inc. (“NantKwest”) and ImmunityBio, Inc. (“ImmunityBio”), including financial estimates and statements as to the expected timing, completion and effects of the

  31. Slide 31: Additional Information and Where to Find It

    Additional Information and Where to Find It • This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy, sell or solicit any securities or any proxy, vote or approval in any jurisdiction pursuant to or in connection with the proposed transac

NantKwest — Merger or Acquisition (December 2020) on 6ix